Home > Press > Real Time PCR Pilot Kits for DNA/RNA Quantification
Acrongenomics one step closer to finalizing its Nano-JETA(TM) technology platform
Acrongenomics Launches First Nano-JETA Real Time PCR Pilot Kits for DNA/RNA Quantification
Athens, Greece | July 01, 2005
Acrongenomics Inc. is pleased to announce the launch of its Nano-JETA(TM) Real Time PCR Pilot kits for DNA/RNA quantification with the use of beta-globin and Ep-CAM gene, respectively.
The results obtained from previous validation and comparative studies bring Acrongenomics one step closer to finalizing its Nano-JETA(TM) technology platform by introducing its first Real Time PCR prototype kits. The kits apply to scientific professionals for demonstration purposes only in order for the company to obtain scientific feedback that will enhance the product's usability and will establish the Nano-JETA(TM) platform.
The DNA/RNA quantification with the Nano-JETA(TM) technology platform is based on Acrongenomics' new mathematical model. Furthermore, Nano-JETA(TM) Real Time PCR delivers rapid quantitative detection of nucleic acids from the 2nd cycle up to the 13th cycle.
Any Real Time PCR thermocycler with specifications to transmit fluorescence data according to Acrongenomics' mathematical model is now able to quantify DNA/RNA copies at any point between the 2nd and 13th cycle.
The pilot kits allow for 24 tests to be performed. Furthermore, the kits contain:
- Certificate of Analysis (COA)
- Comprehensive Manual
- General Mix (GM)
- Pre-Mix1 (PM1)
- Nano-JETA Master Mix (NJMM)
- New mathematical model required for quantification from the 2nd cycle.
Since last year, the Nano-JETA(TM) technology platform by Acrongenomics Inc. has redefined key IVD molecular applications such as PCR, ELISA and Real Time PCR giving them super fast characteristics with up to 100% specificity and sensitivity.
Currently, Acrongenomics is working towards the enrichment of its portfolio with prototype kits for detection and quantification of additional tumor markers expression such as the HER family and vEGF, as well as for viral quantification with markers such as EBV, HBV and HPV.
Molecular diagnostics testing is the fastest-growing segment of the in vitro diagnostics industry. The last four years, clinical market for molecular diagnostic products has increased from $1 billion in 2000 to $2.8 billion in 2004 and sales are expected to exceed $5 billion by 2008 (Biotechnology Associates). More interestingly, D & MD's nanobiotechnology briefing states that the overall market impact of nanobiotech applications is projected to reach $300 billion US by 2020.
Acrongenomics Inc. is a Research and Development nanobiotechnology company specializing in the development of ground-breaking nanomolecular diagnostic tools to diagnose various diseases such as cancer of epithelial origin.
For more information, please visit www.acrongen.com
Copyright © Acrongenomics
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014
European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014
Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014
Tuning light to kill deep cancer tumors: Nanoparticles developed at UMass Medical School advance potential clinical application for photodynamic therapy October 15th, 2014
Physicists build reversible laser tractor beam October 20th, 2014
Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014
1980s aircraft helps quantum technology take flight October 20th, 2014
Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014